Interleukin-21 (IL-21) is a pleiotropic cytokine that plays a pivotal role in modulating both innate and adaptive immune responses. By signaling through its heterodimeric receptor complex—composed of the IL-21 Receptor (IL-21R) and the Common Gamma Chain (γc, CD132)—IL-21 regulates the proliferation, survival, and effector function of CD8+ T cells, NK cells, and B cells. In oncology, IL-21 pathways are harnessed to enhance anti-tumor immunity (often via IL-21-armored CAR-T/NK cells or PD-1/IL-21 bispecific fusion proteins). Conversely, blocking the IL-21 pathway represents a major therapeutic strategy in autoimmune and inflammatory diseases, such as Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).
TarMart Solution Ecosystem & Related Targets
To support both agonist (oncology) and antagonist (autoimmunity) discovery programs, TarMart provides a comprehensive suite of high-purity recombinant proteins, expression vectors, and benchmark controls designed for robust assay development.
"Comprehensive reagent toolkit for IL-21 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| IL-21 Antigen | Recombinant Human IL-21 Protein (HEK293-expressed, native glycosylation, high purity >95%, endotoxin controlled <1.0 EU/μg, sequence verified). Available in His-tag or Fc-fusion formats. | View IL-21 Products |
| IL-21 Receptor (IL-21R) | Recombinant Human IL-21R Extracellular Domain (ECD) fused to Human IgG1 Fc. Essential for receptor binding and competition assays. | View IL-21R Products |
| Common Gamma Chain (IL-2RG) | Recombinant Human IL-2RG/CD132 ECD protein. Crucial for verifying ternary complex assembly and signaling-level interactions. | View IL-2RG Products |
| Gene Delivery | Lentivirus Premade Particles encoding full-length human IL-21 or IL-21R. Engineered for stable cell line generation (e.g., in Jurkat or HEK293 for functional signaling assays). | View IL-21 Products |
| Benchmark Antibody | Anti-IL-21 Recombinant Monoclonal Antibody. Synthesized based on clinical benchmark sequences (e.g., NNC0114-0005) to serve as a positive control in neutralization assays. | View IL-21 Products |
| Validator siRNA | IL-21 and IL-21R Specific siRNA Sets. Designed for target knockdown validation in primary immune cells or reporter cell lines. | View IL-21 Products |
| Synergistic Target (PD-1) | PD-1 Recombinant Proteins and Lentiviruses. PD-1/IL-21 bispecific fusion proteins (muteins) are a prominent modality to target IL-21 activity specifically to tumor-infiltrating lymphocytes. | View PD-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species Cross-Reactivity (Human vs. Cyno vs. Mouse) | Sequence-verified human, cynomolgus, and murine IL-21/IL-21R orthologs with high purity (>95% by SDS-PAGE) to ensure translational assay consistency. |
| Common Gamma Chain (γc) Subfamily Off-Target Screening | A complete screening panel of related cytokines (IL-2, IL-4, IL-7, IL-9, IL-15) and their receptors to rule out off-target binding or cross-activation. |
| Lack of Reliable Reference Standards | Sequence-matched clinical biosimilars (recombinant mAbs) available to calibrate and validate binding and functional neutralization assays. |
| Assay Interference from Misfolded Proteins | Strictly HEK293 mammalian expression systems utilized for all antigens to guarantee native post-translational modifications and correct disulfide bonding. |
Live IL-21 R&D Tracker
The therapeutic landscape for IL-21 is evolving rapidly across oncology and immunology. Stay updated with real-time clinical and scientific progress:
Global Clinical Landscape & Future Outlook
The exploitation of the IL-21 pathway is bifurcated into two distinct therapeutic strategies. In oncology, systemic administration of wild-type IL-21 has historically been limited by a narrow therapeutic window and dose-limiting toxicities. Consequently, current R&D is heavily focused on targeted IL-21 delivery, prominently through bispecific antibody-cytokine fusion proteins (immunocytokines) such as PD-1-targeted IL-21 muteins. These molecules are designed with attenuated IL-21 activity (muteins) that selectively activates tumor-specific CD8+ T cells expressing PD-1, avoiding systemic immune activation. In contrast, the autoimmune landscape is focused on blocking IL-21/IL-21R interactions using neutralizing monoclonal antibodies to treat conditions like Lupus and Sjogren's syndrome.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Fusion Proteins (mAbs-Cytokines) | Akeso (AK115), Bristol Myers Squibb (BMS-986097) | Advanced Solid Tumors, Non-Small Cell Lung Cancer (NSCLC) | Affinity-attenuated IL-21 mutein validation (Requires highly precise recombinant IL-21R and IL-2RG binding assays via SPR). |
| Neutralizing Monoclonal Antibodies (mAbs) | Novo Nordisk (NNC0114-0005) | Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, Sjogren's | Receptor blocking and neutralization assays (Requires high-purity IL-21 and IL-21R ECD proteins, and sequence-verified benchmark antibodies). |
| Armored Cell Therapies (CAR-T / CAR-NK) | Academic Institutions, Biotech Startups | B-cell Malignancies, Solid Tumors | Stable expression verification (Requires Lentivirus Premade Particles for target over-expression and validation). |